Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). T.

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - CEO Jennifer Jarrett - COO Bob Goeltz - CFO Dimitry Nuyten - CMO Juan Jaen - President Conference Call Participants Kaveri Pohlman - BTIG Peter Lawson - Barclays Ashiq Mubarack - Citi Jonathan Miller - Evercore ISI Jason Zemansky - Bank of America Jeff La Rosa - Leerink Partners Rosemary Li - Cantor Fitzgerald Operator Hello, all and welcome to Arcus Biosciences First Quarter 2024 Earnings Call. My name is Lydia, and I'll be your operator today.

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $1.09 per share a year ago.

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple common cancers. “.

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. The fireside chat will take place on Thursday, May 16th, 2024 at 10:00am PT. A live webcast of the fireside chat will be available by visiting.

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies' portfolio of.

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2024. Investors interested in listening to the c.

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a, AXL and PD-1 – across multiple.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company's financial results for the quarter and year ended December 31st, 2023. Investors interested in l.

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Adicet Bio, Inc.

ArriVent Biopharma Inc

CG oncology Inc

Corbus Pharmaceuticals Holdings

Vera Therapeutics

As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.

Insider Buying at These Biotechs Is Huge

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer drugs.

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies' joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. ARC-8 is the study of quemliclustat, an investigational small molecule CD73 inhibitor, plus chemotherapy with or without zimberelimab, an investigational anti-PD-1 antibody, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). The results will be presented during t.

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Agenus

Bristol-Myers

Compugen

GlaxoSmithKline

iTeos Therapeutics, Inc.

Merck

Novartis

Pfizer

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Arlo Technologies Inc

Catalyst Pharmaceuticals

Digi

Dynavax Technologies

Green Plains

Helix Energy Solutions Group

Ironwood Pharma

Ligand Pharmaceuticals

Livent Corp

ModivCare

Payoneer Global

Pacira Pharmaceuticals

Patterson-UTI Energy

SMART Global Hlds

Talos Energy Inc

Vir Biotechnology

Xencor

Xperi

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:

20 favorite small-cap stocks for 2024 among Wall Street analysts

Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. The company's most advanced molecule, domvanalimab, is being investigated in lung cancer and upper GI tract cancers in collaboration with Gilead Sciences. Preliminary findings from the EDGE-Gastric study showed a positive response rate of 56% in patients receiving the dom-zim-chemo combination for upper GI cancers.

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Exelixis

ALAMEDA, Calif. and HAYWARD, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis i.

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Avid Bioservices

NVIDIA

PulteGroup

Royal Caribbean Cruises

Tesla

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.

From laggards to leaders: Small caps on the rise

DISH Network

Enviri Corp

Organon & Co

REGENXBIO

Semtech

ViaSat

It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.

It's Small Stocks' Time To Rally — Analysts Like These 11 Best

Domvanalimab, Arcus Biosciences' Phase 3 cancer immunotherapy drug, shows promise in treating lung and gastrointestinal cancers, but faces a competitive anti-TIGIT market. Arcus experienced a slight revenue drop and increased net loss in Q3 2023, with significant R&D spending and share dilution concerns. Financially stable in the short term with a 39-month cash runway, but long-term sustainability and additional financing needs are potential issues.

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL. The fireside chat will take place on Tuesday, November 28th, 2023 at 7:55am ET. A live webcast of the fireside chat will be available by vi.

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Arcus Biosciences, Inc. (NYSE:RCUS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Pia Eaves - Head of Investor Relations And Strategy Terry Rosen - Co-Founder, Chairman & CEO Dimitry Nuyten - Chief Medical Officer Jennifer Jarrett - COO & Director Robert Goeltz - Principal Financial & Accounting Officer & CFO Juan Jaen - President and Head of Research Conference Call Participants Yigal Nochomovitz - Citigroup Jonathan Miller - Evercore ISI Peter Lawson - Barclays Bank Robin Karnauskas - Truist Kaveri Pohlman - BTIG Mara Goldstein - Mizuho Securities Rosemary Li - Cantor Fitzgerald & Co. Jason Zemanski - Bank of America Operator Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions.

Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript

News for Arcus Biosciences Stock (RCUS)